Growth Potential of Specific Biomarker-Based Tests: White Paper
Loading...
Published Feb 9, 2016 |
3 Pages |
Pub ID: KLI5878138
This White Paper, Growth Potential for Specific Biomarker-Based Tests discusses the market environment for tests involving a biomarker. Markers are "scored" according to their revenue growth potential compared to each other. A market and forecast for all tests are provided, as well as a list of companies that are involved in the market. Markers discussed include: CEA, HIV Rapid Marker-Based, AFP, FOB, Rapid PSA, NMP22, Cardiac Markers-Acute, C difficile Marker-Based, hsCRP, HIV Marker-Based, STD Marker-Based, proBNP, PT/INR, Malaria Markers, Thyroid Marker-Based, PSA, CA125, HbA1c. For specific dollar figures and growth rates, Kalorama's full-length study on Biomarker Markets should be consulted.
- Overview
- Specific Marker-Based Tests Revenue Growth Score
- Companies in the Market
- About the Report
Most Popular Research
- Walk-in Store Clinics (Retail Clinics) Bring Healthcare to Consumers, While Other Venues Wait for Patients
- China's 3.2 Billion-Dollar In Vitro Diagnostics Market: Opportunity for Surplus Growth
- The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 11th Edition
- No Easy Road for POC Molecular Diagnostics in Developing World: White Paper
- The Global Market for Medical Devices, 8th Edition (40+ Specific Device Markets and 23 Country Markets Forecasted to 2022)
- The Market Share Picture in the Point-of-Care Diagnostics Market